Puma Biotechnology Inc (NASDAQ:PBYI) has received a consensus rating of “Hold” from the fourteen brokerages that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $63.11.

A number of research analysts have issued reports on the stock. Royal Bank of Canada increased their target price on shares of Puma Biotechnology to $26.00 and gave the stock a “sector perform” rating in a research report on Thursday. Goldman Sachs Group upgraded shares of Puma Biotechnology from a “sell” rating to a “neutral” rating and decreased their target price for the stock from $36.00 to $28.00 in a research report on Monday, November 19th. Zacks Investment Research lowered shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. Bank of America lowered shares of Puma Biotechnology from a “buy” rating to an “underperform” rating in a research report on Friday, November 2nd. Finally, Barclays lowered shares of Puma Biotechnology from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $72.00 to $29.00 in a research report on Friday, November 2nd.

PBYI traded down $0.56 on Monday, reaching $23.17. The company had a trading volume of 1,079,298 shares, compared to its average volume of 849,921. Puma Biotechnology has a fifty-two week low of $17.60 and a fifty-two week high of $108.20. The firm has a market cap of $904.94 million, a P/E ratio of -2.95 and a beta of 0.22. The company has a debt-to-equity ratio of 2.64, a quick ratio of 2.96 and a current ratio of 3.01.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.97) by $0.60. Puma Biotechnology had a negative net margin of 73.45% and a negative return on equity of 301.41%. The firm had revenue of $62.60 million for the quarter, compared to analyst estimates of $57.94 million. During the same quarter in the prior year, the business posted ($1.36) EPS. The business’s revenue was up 926.2% compared to the same quarter last year. As a group, equities analysts forecast that Puma Biotechnology will post -3.19 earnings per share for the current year.

In related news, insider Charles R. Eyler sold 1,239 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $22.77, for a total transaction of $28,212.03. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 21.50% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of PBYI. Resources Management Corp CT ADV acquired a new stake in shares of Puma Biotechnology during the 3rd quarter worth approximately $101,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Puma Biotechnology during the 2nd quarter worth approximately $141,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Puma Biotechnology during the 3rd quarter worth approximately $213,000. Pacer Advisors Inc. acquired a new stake in shares of Puma Biotechnology during the 3rd quarter worth approximately $251,000. Finally, Royal Bank of Canada boosted its position in shares of Puma Biotechnology by 271.3% during the 1st quarter. Royal Bank of Canada now owns 4,021 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 2,938 shares in the last quarter. Institutional investors and hedge funds own 91.64% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Further Reading: Depreciation

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.